Abstract
Adeno-associated virus (AAV) (type 2) is a popular human gene therapy vector with a long active transgene expression period and no reported vector-induced adverse reactions. Yet the basic molecular biology of this virus has not been fully addressed. One potential gene at the far 3′ end of the AAV2 genome, previously referred to as X (nt 3929 to 4393), overlapping the 3′ end of the cap gene, has never been characterized, although we did previously identify a promoter just up-stream (p81). Computer analysis suggested that X was involved in replication and transcription. The X protein was identified during active AAV2 replication using a polyclonal antibody against a peptide starting at amino acid 98. Reagents for the study of X included an AAV2 deletion mutant (dl78-91), a triple nucleotide substitution mutant that destroys all three 5′ AUG-initiation products of X, with no effect on the cap coding sequence, and X-positive-293 cell lines. Here, we found that X up-regulated AAV2 DNA replication in differentiating keratinocytes (without helper virus, autonomous replication) and in various forms of 293 cell-based assays with help from wild type adenovirus type 5 (wt Ad5) or Ad5 helper plasmid (pHelper). The strongest contribution by X was seen in increasing wt AAV2 DNA replication in keratinocytes and dl78-91 in Ad5-infected X-positive-293 cell lines (both having multi-fold effects). Mutating the X gene in pAAV-RC (pAAV-RC-3Xneg) yielded approximately a ∼33% reduction in recombinant AAV vector DNA replication and virion production, but a larger effect was seen when using this same X-knockout AAV helper plasmid in X-positive-293 cell lines versus normal 293 cells (again, multi-fold). Taken together these data strongly suggest that AAV2 X encodes a protein involved in the AAV life cycle, particularly in increasing AAV2 DNA replication, and suggests that further studies are warranted.
Highlights
First utilized in 1984 [1,2,3,4], adeno-associated virus (AAV) is rapidly growing in popularity as a preferred gene therapy vector with a long transgene delivery period and high safety record [5,6,7]
This study demonstrates that when the associated virus type 2 (AAV2) X is present it increases AAV2 autonomous DNA replication in differentiating keratinocytes, its natural host tissue, in AAV2 DNA replication in Ad5-infected 293 cells, and rAAV2/eGFP replication/virion production in HEK 293 cells with complementation by pHelper and pAAV-RC plasmids
It should be noted that Buller and Rose (1978) found AAV2-induced proteins of 16 and 25 kDa in size [16] and one of these may be the X protein
Summary
First utilized in 1984 [1,2,3,4], adeno-associated virus (AAV) (type 2) is rapidly growing in popularity as a preferred gene therapy vector with a long transgene delivery period and high safety record [5,6,7]. From the sequencing of adeno-associated virus type 2 (AAV2) in 1983 and the phenotypic study of AAV mutants, there have been three trans phenotypes identified within the AAV2 genome [1,8]. The rep phenotype, defective for DNA replication and transcription, encodes replication/transcription factor proteins Rep, Rep, Rep, and Rep. The rep phenotype, defective for DNA replication and transcription, encodes replication/transcription factor proteins Rep, Rep, Rep, and Rep40 Another trans phenotype discovered is lip (described as inf by Barrie Carter’s group) [1,8] which produces viral particles of low infectivity (missing VP1). A fourth trans phenotype, the AAP gene, involved in virion maturation, has been identified by the Kleinschmidt group [9]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.